Regenerative Medicine Program (RMP)
At Bright Cell Health Care Institute, we are providing the first clinical grade stem cell-based products in our portfolio within the Regenerative Medicine Program (RMP). We also have the most medical advances in Regenerative and Anti-aging medicine, some of the services we provide are Exosome and Stem Cell therapies for clients to optimize healing, reverse aging and to prevent degeneration at a cellular level.
Clinical Grade Product Quality
Innovation to improve the quality of life for patient a reliable option for state-of-the-art medical therapy.
Effective IND
After thoroughly reviewed by FDA, CFDA, CDPH, the clinical trials of hUC-Mesemchymal Stem Cells(hUC-MSCs) for several indication were initialed in the U.S and worldwide respectively under effective investigation New Drug Applications (IND)
Compliance
The product manufacture for Bright Cell Healthcare Institute is fully and strictly compliant to U.S FDAs criteria of investigation cell drug from donor screenings to cGMP laboratory, from animal studies to clinical data, from stem cell bank to final released product that are all being completely test under the investigation of U.S FDA.
Extreme
Bright Cell Healthcare Institute’s products are recognized as the top tier clinical-grade MSCs in the industry with high purity, high viability and high biological potency as well as stable karyotype, being widely used in academic and clinical.
Why Mesenchymal Stem Cells?
Among various types of stem cells, Mesenchymal Stem Cells (MSCs) are widely considered as the most potent tool of cell therapy that may pass through the FDA's investigation and reach the market following to Hematopoietic Stem Cells (HSCs)
30
Years
Since Dr. Arnold Caplan gave the name to Mesenchymal Stem Cells in 1992, MSCs have been studied for cell biology, mechanisms, and broad-ranging clinical potential. With the efforts of global researchers, MSC therapeutic paradigm shifted from cell replacement to paracrine provider that presents the possibility to become a promising drug.
+1,100
Clinical Trials
Based on the records on clinicaltrials.gov, there were 244 trials in the US and more than1,110. Trials in the worldwide associated with MSCs by Dec 2023. The conditions including Alzheimer's disease, Diabetes mellitus, System Lupus, Cardiac injuries and Aging frailty are totally 932 that shows the potential board spectrum of MSCs therapeutic.
+50,000
Patients
Given the data from more than 50,000 patients enrolled into designed trials associated with MSCs by far, the excellent safety profile and promising therapeutic efficacy inspired scientists, physicians, and entrepreneurs to discover further to make longevity dream come true.
Copyright © 2024 Brightcell-Healthcare.com All rights reserved 